SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the focal point, with traders watching guidance, subscriber engagement, advertising growth, and content strategy amid leadership changes and layoffs. Bearish concerns about competition, content quality, and slowing growth contrast with bullish hopes that low expectations and ad expansion could support a positive reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is drawing attention as traders position around the full Phase 3 melanoma cancer-vaccine data presentation at ESMO, following previously reported positive topline results. Bulls see the readout as validation of the oncology pipeline, while skeptics warn that expectations and valuation are elevated and debate whether the event could prompt profit-taking.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is drawing attention, with traders attributing the move to possible short covering and technical buying rather than a confirmed new company announcement. The broader debate centers on upcoming DM1 and FSHD siRNA data: Novartis/Aviditys DM1 trial failure raised concerns about whether target knockdown can translate into patient benefit, while some traders argue Sareptas distinct delivery approach and the loss of a competitor could be favorable.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are falling amid concern over plans to list its Monee financial-services arm and launch Sea Cloud, which traders worry could add spending and strategic uncertainty. The community is split between viewing a Monee separation as a potential value unlock and fearing it could weaken the remaining business, while some see the selloff as an overreaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings beat and a new buyback authorization, as traders focus on narrowed full-year profit guidance with an unchanged midpoint and weaker vehicle sales. Some view the drop as overdone given the stronger cash-flow outlook and buyback, while others see the outlook as too cautious to offset the earnings-day disappointment.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook drew attention as shares sold off despite strong demand, with traders frustrated by the reaction. The debate centers on whether higher costs, weaker cash generation and an insurance loss outweigh the stronger orders and guidance.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside new BRIUMVI data. Traders are hopeful azer-cel could add a growth opportunity beyond BRIUMVI, while recognizing the early readouts efficacy is uncertain; continued BRIUMVI sales growth is the more established part of the story.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers push to a fresh 52-week high is drawing attention, with traders celebrating a long-awaited recovery and debating whether the breakout can hold or will meet resistance. Some point to defensive-sector demand and pipeline progress, while others say the move needs a clearer company-specific catalyst.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention to the drugs potential and analyst optimism. Traders are debating whether the placebo-adjusted benefit is modest and whether agitation concerns and higher discontinuations could limit the upside, with some viewing the move as vulnerable to a fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a balance-sheet and strategic boost. Others question the deal because the divested unit contributes revenue, raising concerns about debt and the outlook for the remaining business; some traders are also taking profits after the surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Virtus Dividend, Interest & Premium Strategy Fund Announces Final Results of Tender Offer

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the Fund) today announced the final results of its previously announced tender offer (Tender Offer) to acquire up to 25% of its outstanding shares. The Tender Offer expired October 5, 2026, at 5:00 p.m. (Eastern). The Fund accepted...

Virtus Dividend, Interest & Premium Strategy Fund Announces Preliminary Results of Tender Offer

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the Fund) today announced preliminary results of its previously announced tender offer (Tender Offer) to acquire up to 25% of the Funds outstanding shares. The Tender Offer expired on October 5, 2026, at 5 p.m. (Eastern). Based on...

Virtus Dividend, Interest & Premium Strategy Fund Announces Distribution and Discloses Sources of Distribution Section 19(a) Notice

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) today announced the following quarterly distribution: Ticker Amount of Distribution Ex-Date/Record Date Payable Date NFJ $0.305 September 14, 2026 September 29, 2026 Under the terms of its Managed Distribution Plan, the Fund will seek to...

Virtus Dividend, Interest & Premium Strategy FundAnnounces Commencement of Tender Offer

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the Fund) today announced the commencement of a tender offer (Tender Offer) beginning September 1, 2026, and expiring at 5:00 p.m. (Eastern) on October 5, 2026, unless the Tender Offer is extended (the Expiration Date).The Fund, as...

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) today announced the following quarterly distribution: Ticker Amount of Distribution Ex-Date/Record Date Payable Date NFJ $0.305 June 15, 2026 June 29, 2026 Under the terms of its Managed Distribution Plan, the Fund will seek to maintain...

Virtus Closed-End Funds Announce Results of Joint Annual Meeting of Shareholders

Virtus Artificial Intelligence & Technology Opportunities Fund (NYSE: AIO), Virtus Convertible & Income Fund (NYSE: NCV), Virtus Convertible & Income Fund II (NYSE: NCZ), Virtus Diversified Income & Convertible Fund (NYSE: ACV), Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ), Virtus...

Saba Capital Reaches Agreement With Virtus Dividend, Interest & Premium Strategy Fund

Saba Capital Management, L.P. (together with certain of its affiliates, Saba) today announced that it has entered into a standstill agreement with Virtus Investment Advisers, LLC and Virtus Dividend...

Virtus Dividend, Interest & Premium Strategy Fund Announces Tender Offer

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the Fund) today announced that its Board of Trustees has approved a tender offer (Tender Offer) intended to enhance shareholder value, provide shareholders with an additional source of liquidity for their investment, and provide the...

Virtus Dividend, Interest & Premium Strategy Fund Announces Renewal of Share Repurchase Program

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the Fund), a closed-end fund, announced today that the Board of Trustees approved the renewal of its open market share repurchase...

Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) today announced the following quarterly distribution: Ticker Amount of Distribution Ex-Date/Record Date Payable Date NFJ $0.305 March 16...

Virtus AllianzGI Dividend, Interest & Premium Strategy Fund is a closed-end investment fund. It seeks current income and gains, with a secondary objective of long-term capital appreciation. The company was founded on August 20, 2003 and is headquartered in Greenfield, MA.

Virtus AllianzGI Dividend Interest & Premium Strategy Fund

Neutral Sentiment

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$14.73
Prev Close	$14.57
Open	$14.56
Dividend Yield	9.05%
50-Day Moving Average	$15.26
Beta	0.73
Avg. Volume	285,020.06
PE Ratio	4.06

52-Week High	$15.75
52-Week Low	$12.25
Market Capitalization	$1.35B
EPS (Annual)	$1.59
Price to Book	0.89
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

NFJ Fundamentals